Tergenpumatucel-L: Phase IIb/III started

NewLink began an open-label Phase IIb/III trial to compare 2 dosing schedules of tergenpumatucel-L at 300 million cells via intradermal injections vs. 75 mg/m 2 IV docetaxel every 3 weeks for 4 doses ...